Presentation is loading. Please wait.

Presentation is loading. Please wait.

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Similar presentations


Presentation on theme: "From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness."— Presentation transcript:

1 From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness Analysis Ann Intern Med. 2009;151(9): doi: / Figure Legend: * See Appendix for discussion of this strategy. Date of download: 10/17/2017 Copyright © American College of Physicians. All rights reserved.

2 From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness Analysis Ann Intern Med. 2009;151(9): doi: / Figure Legend: The evolution of functional disability and radiographic joint damage (erosion) after disease onset are displayed. The HAQ score ranges from 0 to 3 (maximum functional disability). Radiographic damage ranges from 0% (no joint damage) to 100% (total joint damage). DMARD = disease-modifying antirheumatic drug; HAQ = Health Assessment Questionnaire. Date of download: 10/17/2017 Copyright © American College of Physicians. All rights reserved.


Download ppt "From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness."

Similar presentations


Ads by Google